Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

NCT06243666 ACTIVE_NOT_RECRUITING

The primary objective of this study is to evaluate the protective efficacy against future infections of HPV types 16/18 or related diseases and immuno-persistence (type specific IgG antibody) of the bivalent HPV vaccine in young female populations aged 9-17 years.

Details

Lead sponsor	Xiamen University
Status	ACTIVE_NOT_RECRUITING
Enrolment	2188
Start date	Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Dec 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Cervical Intraepithelial Neoplasia
• Cervical Cancer
• Persistent Infection

Interventions

• Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
• No intervention
• Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)

Countries

China